The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...

Bullous Pemphigoid Causes. Bullous pemphigoid is an autoimmune disease, which means something causes your immune system to attack your body’s cells.But researchers don’t know why this happens ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

People with bullous pemphigoid are typically given topical or oral steroids to treat the “tense blisters” that show up on the arms, legs, lower body and occasionally in the mouth.

Bullous pemphigoid is the most common blistering autoimmune disease of the skin 1,2; it is manifested by cutaneous blisters without mucosal involvement. 3 Histologic features include subepidermal ...